Advertisement

Meet the Experts

Aditya Bardia
Attending Physician, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Specialty: Breast Cancer

Dr. Aditya Bardia, a board-certified medical oncologist, is an Attending Physician at Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston. As the Director of Breast Cancer Research Program at the MGH Center for Breast Cancer, Dr. Bardia is interested in advancing research to improve the outcomes with breast cancer. Dr. Bardia has led the clinical development of antibody drug conjugate (ADC), sacituzumab govitecan, which was recently provided accelerated approval for patients with metastatic triple negative breast cancer. Dr. Bardia has received several research awards including outstanding award for research excellence at Mayo Clinic, Young Investigator Award from ASCO, and Douglas Family Foundation prize for excellence in oncology research at MGH. Dr. Bardia is the editor of precision medicine clinic section of The Oncologist, co-leader of the Molecular and Precision (MAP) tumor board at MGH, and editorial board member of ASCO molecular oncology tumor board.

Disclosures

Consulting or Advisory Role: bioTheranostics, Daiichi Sankyo/Astra Zeneca, Foundation Medicine, Genentech, Genentech/Roche (Inst), Immunomedics, Immunomedics (Inst), Innocrin Pharma (Inst), Merck, Novartis, Novartis (Inst), Pfizer, Pfizer (Inst), Philips, Puma Biotechnology, Radius Health, Radius Health (Inst), Sanofi, Spectrum Pharmaceuticals; Research Funding: AstraZeneca/Daiichi Sankyo (Inst), Genentech (Inst), Immunomedics (Inst), Merck (Inst), Novartis (Inst), Pfizer (Inst), Radius Health (Inst), Sanofi (Inst)

Continue Reading
Aparna Raj Parikh, MD
Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA; Attending Physician, Director MGH Cancer Center Global Cancer Care Program
Specialty: Gastrointestinal Cancers

Dr. Parikh is GI oncologist at the MGH Cancer Center and the Director of the Global Cancer Program. She primarily sees patients with colorectal cancer and pancreatic cancer and has an interest in younger adults with these cancers. She sits on the NCCN guidelines committee for CRC and is a thought leader in liquid biopsies leading one of the first prospective national studies in colorectal cancer.

Disclosures

Consulting or Advisory Role: Foundation Medicine, Lilly, Natera, PureTech; Research Funding: Array BioPharma (Inst), Bristol-Myers Squibb (Inst), Genentech (Inst), Guardant Health (Inst), Lilly (Inst), Novartis Pharmaceuticals UK Ltd. (Inst), Plexxikon (Inst), Tesaro (Inst)

Continue Reading
Brad McGregor, MD
Lank Center for GU Oncology, DFCI, Harvard Medical School, Boston, MA, USA
Specialty: Genitourinary Cancers

Dr. Bradley A. McGregor is the Clinical Director for the Lank Center of Genitourinary Oncology serving as a Medical Oncologist specializing in genitourinary malignancies at the Dana-Farber Cancer Institute. Completing is undergraduate and medical school education at Tufts University; he then joined the United States Air Force at the San Antonio Uniformed Services Health Education Consortium. While in the military, he completed his post-graduate training in internal medicine, medical oncology and hematology. In addition, he served in Afghanistan as the Deputy Commander for the NATO led Medical Training Advisory Group where he mentored the Afghan physicians. Reaching the rank of Lieutenant Colonel and receiving the Meritorious Service medal, Dr. McGregor left the Air Force in July of 2016 and came to Dana-Farber. He is actively involved in clinical research in GU malignancies serving as primary investigator for several ongoing trials.

Disclosures

Consulting or Advisory Role: Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Dendreon, Eisai, EMD Serono, Exelixis, Genentech/Roche, Janssen Oncology, Nextar, Pfizer, Seattle Genetics/Astellas; Research Funding: Bristol-Myers Squibb (Inst), Calithera Biosciences (Inst), Exelixis (Inst), Seattle Genetics/Astellas (Inst)

Continue Reading
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci
University of Birmingham, Birmingham, UK
Specialty: Hematologic Malignancies

Professor Charles Craddock is Director of the Birmingham Centre for Cellular Therapy and Transplant Blood, University Hospitals, Birmingham and Professor of Haemato-oncology, University of Birmingham. He trained in haematology at the Hammersmith Hospital in London, the Institute of Molecular Medicine at the University of Oxford, and the University of Washington in Seattle, USA. Professor Craddock is Chair of the UK Stem Cell Strategic Oversight Committee and was Medical Director of Anthony Nolan from 2010–2014. He was elected President of the British Society of Haematology in 2017. He drove the establishment and subsequent expansion of the £7 million Centre for Clinical Haematology at the Queen Elizabeth Hospital and, as Director of Birmingham Health Partners, led the development of the £24 million Birmingham Institute of Translational Medicine, which opened in 2015. Professor Craddock’s main research interests include the development of novel drug and transplant therapies in myeloid leukemias and he leads the UK Haemato-oncology Trials Acceleration Programme. He pioneered the development of a UK stem cell transplant trials network, IMPACT, one of only two worldwide, which was launched in 2017. He has published more than 225 papers in peer reviewed journals. Professor Craddock was awarded the CBE for services to medicine and medical research in the 2016 New Year’s Honours list and elected a Fellow of the Academy of Medical Sciences in 2020.

Disclosures

Honoraria: Abbvie, Celgene, Jazz Pharmaceuticals, Janssen, Pfizer, Daiichi Sankyo, Amgen, Astellas Pharma; Consulting or Advisory Role: Daiichi Sankyo, Abbvie, Janssen, Novartis, Bristol-Myers Squibb, Pfizer, Astellas Pharma, Daiichi Sankyo, Eurocept; Speakers’ Bureau: Abbvie, Janssen, Novartis, Roche, Bristol-Myers Squibb, Pfizer, Astellas Pharma, Daiichi Sankyo, Eurocept; Research Funding: Celgene, Jazz Pharmaceuticals, Kite Pharma, Jazz Pharmaceuticals; Expert Testimony: Daiichi Sankyo; Travel, Accommodations, Expenses: Celgene, Jazz Pharmaceuticals, Daiichi Sankyo

Continue Reading
Heather A. Wakelee, FASCO, MD
Professor of Medicine and Chief Division of Oncology, Stanford Cancer Institute/Stanford University, CA, USA
Specialty: Lung Cancer

Dr. Heather Wakelee is a Professor of Medicine and Chief in the Division of Oncology at Stanford University. She is also the Deputy Director of the Stanford Cancer Institute. She has authored or co-authored over 250 medical articles on lung cancer and other thoracic malignancies and is involved in dozens of clinical trials related to lung cancer therapy and diagnostics. Her research focuses on many specific lung cancer subtypes defined by specific mutations in EGFR, ALK, ROS1, RET, BRAF and others.  She has been a leader in trials of adjuvant therapy for lung cancer.  Additionally, she collaborates extensively with colleagues focused in biomarkers and others working in population science research.  Dr. Wakelee is active in multiple national and international lung cancer research organizations including serving as the President-Elect for the International Association for the Study of Lung Cancer (IASLC), co-chair of the thoracic committee and Stanford Principal Investigator for the Eastern Cooperative Oncology Group (ECOG-ACRIN), and as a Fellow of the American Society of Clinical Oncology (FASCO).

Disclosures

Honoraria: Abbvie, Celgene, Jazz Pharmaceuticals, Janssen, Pfizer, Daiichi Sankyo, Amgen, Astellas Pharma; Consulting or Advisory Role: Daiichi Sankyo, Abbvie, Janssen, Novartis, Bristol-Myers Squibb, Pfizer, Astellas Pharma, Daiichi Sankyo, Eurocept; Speakers’ Bureau: Abbvie, Janssen, Novartis, Roche, Bristol-Myers Squibb, Pfizer, Astellas Pharma, Daiichi Sankyo, Eurocept; Research Funding: Celgene, Jazz Pharmaceuticals, Kite Pharma, Jazz Pharmaceuticals; Expert Testimony: Daiichi Sankyo; Travel, Accommodations, Expenses: Celgene, Jazz Pharmaceuticals, Daiichi Sankyo

Continue Reading
Ian Chau, MD
Department of Medicine, Royal Marsden Hospital, London & Surrey, UK
Specialty: Gastrointestinal Cancers

Dr Ian Chau holds the position of consultant medical oncologist within the Gastrointestinal and Lymphoma Units at Royal Marsden Hospital and Reader at the Institute of Cancer Research, London & Surrey, UK.  He qualified from the United Medical & Dental Schools of Guy’s and St. Thomas’ Hospitals, University of London, before undergoing medical oncology specialist training and clinical research fellowship at the Royal Marsden Hospital.  He is the chief or principal investigator of multiple phase I, II and III clinical trials evaluating novel treatment strategies and agents in various cancer signalling pathways.  He serves or has served on American Society of Clinical Oncology (ASCO) Scientific Program Committee, ASCO Education Committee, European Society of Medical Oncology (ESMO) Congress Steering Committee, ESMO Asia Scientific Programme and Steering Committee, ESMO Educational Committee and UK National Cancer Research Institute (NCRI) Colorectal Cancer and Pancreatic Cancer Clinical Study Groups,  He was the track leaders for Gastrointestinal (non-colorectal) Cancer for ASCO Annual Meeting Education Committee and ESMO Scientific Committee as well as Scientific Chairman for ESMO Asia Congress in 2019.  He is on the Trial Management Groups and Trial Steering Groups of multiple national and global phase II-III gastrointestinal cancer and lymphoma trials.   He serves or has served on the UK National Institute of Health and Care Excellence (NICE) Clinical Guideline Development Group for non-Hodgkin’s Lymphoma, ASCO Expert Panel for the Management of Immunotherapy Toxicities Guideline and ESMO Clinical Practice Guidelines for Hepatocellular Carcinoma panel.  He is the recipient of Swedish Society of GI Oncology Bengt Glimelius Award 2016, merit awards from ASCO Gastrointestinal Cancer Symposium, The Royal Society of Medicine Section of Oncology Clinical Prize, fellowships from the European School of Oncology and ASCO/AACR/FECS Clinical Cancer Research Workshop.  He has given invited lectures in over 30 countries.  He has served on international drug development advisory boards and has peer review publications in the New England Journal of Medicine, The Lancet, The Lancet Oncology, Journal of Clinical Oncology and other leading oncology / biomedical journals.

Disclosures

Honoraria: Lilly; Consulting or Advisory Role: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Merck Serono, MSD Oncology, Oncologie, Pierre Fabre, Roche/Genentech; Research Funding: Janssen-Cilag (Inst), Lilly (Inst); Travel, Accommodations, Expenses: Bristol-Myers Squibb, Lilly, Merck Serono, MSD

Continue Reading
Jesus G. Berdeja, MD
Director of Multiple Myeloma Research, Sarah Cannon Research Institute, Nashville, TN, USA
Specialty: Hematologic Malignancies

Jesus G. Berdeja received his undergraduate degree from Stanford University and medical degree from Harvard University.  He completed his internship and residency in the Department of Internal Medicine at the University of California in San Francisco and fellowships in medical oncology and hematology at Johns Hopkins University School of Medicine in Baltimore. Prior to joining the staff at the Sarah Cannon Research Institute and Tennessee Oncology, Dr. Berdeja held appointments in the Stem Cell and Bone Marrow Transplant Program and the Division of Hematology and Oncology at Loma Linda University in Loma Linda, California.

Dr. Berdeja has been certified a Diplomate in internal medicine, medical oncology, and hematology by the American Board of Internal Medicine. Additionally, he is an active member of several professional organizations, including the International Myeloma Society, the American Society of Clinical Oncology, the American Society of Hematology, the International Myeloma Working Group, the Clinical Trials Myeloma Intergroup Committee, and the Center for International Blood and Marrow Transplant Research Plasma Cell Working Group.

An active researcher, Dr. Berdeja has been the principal investigator on a number of funded clinical trials in the field of multiple myeloma. He has published extensively in the peer-reviewed literature and is a frequent invited lecturer.

Disclosures

Consulting or Advisory Role: Bluebird Bio (Inst), Bristol-Myers Squibb (Inst), Celgene (Inst), crispr therapeutics (Inst), Janssen (Inst), Karyopharm Therapeutics (Inst), Kite, a Gilead company (Inst), Legend Biotech (Inst), Secura Bio (Inst), SERVIER (Inst), Takeda (Inst); Research Funding: Abbvie (Inst), Acetylon Pharmaceuticals (Inst), Amgen (Inst), Bluebird Bio (Inst), Bristol-Myers Squibb (Inst), Celgene (Inst), Celularity (Inst), Constellation Pharmaceuticals (Inst), crispr therapeutics (Inst), CURIS (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Glenmark (Inst), Ichnos Sciences (Inst), Janssen (Inst), Kesios Therapuetics (Inst), Lilly (Inst), Novartis (Inst), poseida therapeutics (Inst), Sanofi (Inst), Takeda (Inst), Teva (Inst), Vivolux (Inst)

Continue Reading
Karim Fizazi, MD, PhD
Professor, Institut Gustave Roussy, University of Paris Saclay, France
Specialty: Genitourinary Cancers

Karim Fizazi, MD, PhD, is a medical oncologist at Gustave Roussy Institute, and a full professor in Oncology at the University of Paris Saclay in Villejuif, France.

Prof Fizazi attained his medical degree in 1995. In 1997, he completed a fellowship at Gustave Roussy. After a visiting professorship at the MD Anderson Cancer Center in Houston from 1999 to 2001 where he was working on preclinical models of bone metastases from prostate cancer, he gained his PhD in Molecular Oncology in 2003. He was head of the Department of Cancer Medicine at Institute Gustave Roussy from 2005 to 2018 and he was promoted a professor at the University of Paris Sud in 2009. He is the President of the French Groupe d’Etude des Tumeurs Genito-Urinaires (GETUG) and the President of the French Study Group of Carcinomas of Unknown Primary (GEFCAPI). Prof. Fizazi is associate editor of European Journal of Cancer and consulting editor of European Urology. He has authored more than 400 peer-reviewed articles.

Amongst his major achievements, Prof. Fizazi demonstrated in 2010 the role of denosumab for the prevention of complications of bony metastases from prostate cancer. Prof. Fizazi established in 2015 the role of early chemotherapy in order to prevent relapse in men with localized prostate cancer at high-risk for relapse in the GETUG 12 trial. Prof. Fizazi was the chair of two major pivotal trials testing next-generation androgen receptor axis targeting agents: LATITUDE which demonstrated in 2017 the impact of abiraterone on survival in men with de novo metastatic prostate cancer, and ARAMIS showed that darolutamide, a drug that was first tested by Prof. Fizazi in phase 1 trials, also improves survival in men with non-metastatic castrate-resistant prostate cancer.

In testicular cancer, Prof. Fizazi established in 2014 a new standard of care for young patients with poor-prognosis germ-cell tumors, thanks to an individualized algorithm of treatment in the GETUG 13 trial, although no significant progress had been provided for these patients in the previous 25 years.

To push forward clinical research on prostate cancer in Europe, Prof. Fizazi created in 2013 the Prostate Cancer Consortium in Europe (PEACE). He’s now head of the two first large PEACE European academic phase III trials: PEACE-1 (testing abiraterone and local radiotherapy in de novo metastatic prostate cancer), which has completed accrual, and PEACE-2 (testing cabazitaxel and pelvic radiotherapy in very high-risk localized prostate cancer). PEACE-4 which is testing the role of aspirin and that of statins in castrate-resistant prostate cancer was also launched in 2019.

Disclosures

Honoraria: Astellas Pharma, Bayer, Janssen, Sanofi; Consulting or Advisory Role: Amgen (Inst), Astellas Pharma, AstraZeneca (Inst), Bayer, Curevac, ESSA (Inst), Janssen Oncology (Inst), Orion Pharma GmbH, Sanofi (Inst); Travel, Accommodations, Expenses: Janssen, MSD

Continue Reading
Marcia S. Brose, MD, PhD, FASCO
Professor, Director, Center for Rare Cancers and Personalized Therapy, Abramson Cancer Center of the University of Pennsylvania, PA, USA
Specialty: Head and Neck Cancers

Marcia S. Brose MD PhD is an Associate Professor at the University Of Pennsylvania School Of Medicine, in the Departments of Otorhinolaryngology: Head and Neck Surgery, and Medicine, division of Hematology/Oncology. Over the past 14 years she has been the Director of the Thyroid Cancer Therapeutics Program. In 2015 she was appointed the Director of the Center for Rare Cancers and Personalized Therapy for the Abramson Cancer Center.

Dr. Brose’s current research interest includes the identification of novel treatments for advanced thyroid cancer, rare solid tumors and those with genetic targets. She runs a clinical research unit and a laboratory aimed at identifying new therapeutic targets for solid tumors through genetic and molecular studies of tumor tissue. She has contributed to over 10 change of practice clinical trials and trials that lead to FDA approvals for new agents, several of which originated in her own investigator initiated trials. She is an international expert and has lectured across the US, Europe, Asia and South America.

Disclosures

Honoraria: Bayer, Eisai, Lilly; Consulting or Advisory Role: Bayer, Blueprint Medicines, Eisai, Exelixis, Lilly, Loxo; Research Funding: Bayer (Inst), Blueprint Medicines (Inst), Eisai (Inst), Exelixis (Inst), Lilly (Inst), Loxo (Inst)

Continue Reading
Martin Reck, MD, PhD
Head of Department of Thoracic Oncology, LungenClinic, Großhansdorf, Germany
Specialty: Lung Cancer

Martin Reck, MD, PhD, is head of the Department of Thoracic Oncology and head of the Clinical Trial Department in the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf, Germany.

He is also Principal Investigator in the Airway Research Center North (ARCN), which is a member of the German Centre for Lung Research (DZL).

Dr Reck has been a Principal Investigator (PI) in various clinical trials since 1993. His main interests are new medical treatments of thoracic malignancies as well as translational research related to predictive markers. A particular focus of his work has been attributed to the clinical development of antiangiogenic compounds. Recently he also has been deeply involved in several key trials with immunotherapies including ipilimumab, PD-1 and PDL-1 antibodies and other agents. As part of this activity he has been the principal investigator of the Keynote 24 trial investigating monotherapy with Pembrolizumab against platinum based chemotherapy in untreated patients with advanced PDL-1 expressing NSCLC (TPS =/> 50%),  IMpower 150 trial and the CheckMate 9LA trial, which evaluated the combination of Nivolumab and Ipilimumab together with a short chemotherapy. Furthermore he has served on various Global Trial Steering Committees.

Besides the European Society of Medical Oncology (ESMO) Dr Reck is member of the International Association for the study of Lung Cancer (IASLC), the American society of Medical Oncology (ASCO), the German Working Group for Lung Cancer, the German Cancer Society (DKG) and the German Society of Pulmonology (DGP).

He has published papers in numerous peer-reviewed journals and is member of the editorial board of Journal of Thoracic Oncology, Annals of Oncology and Lung Cancer.

Disclosures

Consulting or Advisory Role: Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Merck Serono, Mirati Therapeutics, MSD Oncology, Novartis, Pfizer, Roche/Genentech, Samsung Bioepis; Speakers’ Bureau: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Lilly, Merck Serono, Mirati Therapeutics, MSD Oncology, Novartis, Pfizer, Roche/Genentech

Continue Reading
Nadia Harbeck, MD
Director, Breast Center, LMU University Hospital, Munich, Germany
Specialty: Breast Cancer

Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany. She obtained her specialist degree (OB&GYN) at the Technical University of Munich (TUM) and her medical degree from the University of Munich. From 2005-2009, she was an assistant professor and head of Conservative Senology at TUM and from 2009-2011, she was head of the Breast Center at the University of Cologne, Germany.

Professor Harbeck is a member of the expert panel issuing the yearly updated evidence-based AGO Guidelines for breast cancer therapy in Germany (www.ago-online.de). She is scientific director of the West German Study Group (www.wsg-online.com). From 2009-2015, she served on the executive board of the EORTC as the chair of the translational research division. Professor Harbeck is principal investigator or steering committee member of numerous breast cancer trials, particularly with novel targeted compounds. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumours. She has a strong interest in eHealth and is a co-developer of CANKADO, an international digital patient diary (www.cankado.com).

Professor Harbeck has authored more than 480 papers in peer-reviewed journals (h-index 82) and is coordinating editor-in-chief of Breast Care (Karger Publishers). She is a panel member of several international breast cancer consensus conferences, such as for advanced breast cancer (ABC), breast cancer in young women (BCY), and early breast cancer (St Gallen).

In 2020, Professor Harbeck received the 2020 ESMO Lifetime Achievement Award. She has also numerous other recognitions of her clinical and translational research such as the 2015 Bavarian Cancer Patient Award, the 2012 Claudia von Schilling Award, the 2008 EBCC Award (Emmanuel van der Schueren Lecture), the 2002 AGO Schmidt-Matthiesen Award, a 2001 AACR Award, and the 2001 ASCO Fellowship Merit Award for the highest ranking abstract.

Disclosures

Stock and Other Ownership Interests: West German Study Group; Honoraria: Amgen, AstraZeneca, Genomic Health, Novartis, Pfizer, Pierre Fabre, Roche, Zodiac Pharma; Consulting or Advisory Role: Agendia, AstraZeneca, Celgene, Daiichi Sankyo, Lilly, Merck Sharp & Dohme, Novartis, Odonate Therapeutics, Pfizer, Pierre Fabre, Roche/Genentech, Sandoz, Seattle Genetics, West German Study Group (I); Research Funding: Lilly (Inst), Merck Sharp & Dohme (Inst), Novartis (Inst), Pfizer (Inst), Roche/Genentech (Inst)

Continue Reading
Nina Shah, MD
Professor of Clinical Medicine, Division of Hematology-Oncology, University of California San Francisco, CA, USA
Specialty: Hematologic Malignancies

Dr. Shah is a Professor of Clinical Medicine in the Division of Hematology-Oncology at University of California San Francisco.  Her research focuses on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy.  She performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is one of the lead principal investigators for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients.  Additionally, she is the institutional PI for numerous cellular therapy and immunotherapy protocols.

Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation and led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population.  She has published on the link between patient reported outcomes and physical testing in this clinical context and is conducting a study to investigate digital life coaching during transplant recovery.  She is heavily involved in the myeloma research community and led the effort to define myeloma-transplant practice guidelines for the American Society of Blood and Marrow Transplant (ASBMT).  She also serves as a Co-Chair for the Plasma Cell Disorders and Adult Solid Tumors Working Committee at the Center for International Blood & Marrow Transplant Research (CIBMTR) and is a member of the American Society of Hematology Scientific Committee on Plasma Cell Neoplasia.

Disclosures

Consulting or Advisory Role: Bristol-Myers Squibb, Genentech/Abbvie, Indapta Therapeutics, Karyopharm Therapeutics, Oncopeptides, Precision Biosciences, Sanofi, Surface Oncology; Research Funding: Bluebird Bio, Celgene, Janssen, Nektar, Poseida Therapeutics, Sutro Biopharma, Teneobio

Continue Reading
Paolo Zola, MD, PhD
Chair, Gynecological Oncology Unit, University of Turin, Italy
Specialty: Gynecologic Cancers

Paolo Zola, MD, is a Professor in Obstetrics and Gynaecology at the University of Turin. He has been working as an assistant and researcher at the Obstetrics and Gynaecology Institute, “A”, since 1979. He has also been working as a clinical researcher in the university’s Department of Gynaecological Oncology since 1996. He is now the Head of their Oncology Gynecology and Obstetrics Service – SSCVD. His research has been widely published in national and international journals on the topics of Gynecology and Obstetrics, and Oncological gynecology.

Disclosures

Consulting or Advisory Role: AstraZeneca/Merck, Clovis Oncology, Roche; Research Funding: AstraZeneca/Merck, Roche

Continue Reading
Rachel E. Sanborn, MD
Co-Director, Thoracic Oncology Program; Director, Phase I Clinical Trials Program, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA
Specialty: Lung Cancer

Dr. Sanborn is the Co-Director of the Thoracic Oncology Program and Director of the Phase I Clinical Trials Program at the Earle A. Chiles Research Institute at Providence Cancer Institute in Portland, Oregon. She is a member of the Providence Institutional Review Board, the Bonnie J. Addario Lung Cancer Foundation and American Lung Association Registry Strategic Advisory Council, and the American Lung Association Medical Advisory Workgroup.  She has served as co-chair of the Hoosier Cancer Research Network Thoracic Clinical Trials Working Group and is a member of the American Society of Clinical Oncology as well as the International Association for the Study of Lung Cancer.

Disclosures

Honoraria: Amgen, AstraZeneca; Consulting or Advisory Role: AstraZeneca, Blueprint Medicines, Daiichi Sankyo/Lilly, EMD Serono, Genentech/Roche, Janssen Oncology, Macrogenics; Research Funding: AstraZeneca, Bristol-Myers Squibb (Inst), MedImmune (Inst), Merck; Travel, Accommodations, Expenses: AstraZeneca

Continue Reading
Rodabe N. Amaria, MD
Associate Professor, Department of Melanoma - Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA
Specialty: Melanoma/Skin Cancer

Dr. Amaria is an Associate Professor of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center.  Her areas of research interest include tumor infiltrating lymphocytes for treatment of metastatic melanoma and neoadjuvant therapy for clinical stage III melanoma.

Disclosures

Consulting or Advisory Role: Iovance Biotherapeutics, Nektar; Novartis; Research Funding: Array BioPharma (Inst), Bristol-Myers Squibb (Inst), Genentech (Inst), iovance Biotherapeutics (Inst), Merck (Inst), Novartis (Inst)

Continue Reading
Ronan Joseph Kelly, MBA, MD
Director, Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA
Specialty: Gastrointestinal Cancers

Dr. Ronan Kelly, M.B., B.Ch., M.B.A is the Director of the Charles A. Sammons Cancer Center and the W.W. Caruth Jr. Endowed Chair of Immunology at Baylor University Medical Center in Dallas Texas and the Chief of Oncology for the Baylor Scott & White Health System (NTx). As the largest not-for-profit healthcare system in Texas, Baylor Scott & White and their affiliated physicians treat tens of thousands of cancer patients across the state each year. Baylor Scott and White Health’s integrated network of cancer centers is the 3rd largest collection of Commission on Cancer-accredited centers in the United States and the largest network of hospital-based cancer programs in Texas. Dr. Kelly is a Clinical Professor at Texas A&M University and Professor Clinical Science Division at the Translational Genomics Research Institute (TGEN). He remains an Adjunct Associate Professor at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He previously served as the Director of the Gastroesophageal Cancer Therapeutics Program at Johns Hopkins and as the Director of Global Oncology for John Hopkins International. In the latter role, he was responsible for improving the quality of cancer care in all John Hopkins-affiliated hospitals across four continents. He performs translational and clinical research encompassing the discovery and the development of new targeted and immunotherapeutic approaches in the prevention and treatment of gastroesophageal cancer and lung cancer. He is the National and International Principal Investigator on numerous ongoing phase II and phase III studies investigating single agent and combination checkpoint inhibitors in locally advanced and metastatic gastroesophageal cancer. Dr Kelly was the lead investigator and first author for the practice changing Phase III global CheckMate 577 study across 29 countries and 170 sites, which demonstrated the efficacy of adjuvant Nivolumab in resected stage II/III esophageal/gastroesophageal cancer post trimodality therapy. The results of the CheckMate 577 study were published in the New England Journal of Medicine in April 2021. Dr Kelly is the Founder and the Director of the Texas Immuno-Oncology Biorepository which is providing comprehensive, standardized and cutting edge immune monitoring across thousands of real-world cancer patients throughout Texas to enhance cancer therapy and improve biomarker discovery across a diverse community from multiple racial, genomic and social backgrounds. He is the Chair of the International Association for the Study of Lung Cancer (IASLC) Quality and Value Taskforce which is seeking to improve the quality of lung cancer care across the World and he sits on the ASCO Measures Taskforce (lung cancer chair), Quality of Cancer Care Taskforce, International Quality Taskforce and the Clinical Practice Committee. He is currently leading a new initiative between ASCO and the IASLC to improve lung cancer care in Brazil and Spain. He is a taskforce member of the Gastroesophageal Cancer Committee of ECOG and the National Cancer Institute. Dr Kelly is author or co-author of more than 150 publications, including peer-reviewed journal articles, abstracts and book chapters.

Disclosures

Consulting or Advisory Role: AstraZeneca, Bristol-Myers Squibb, Daiichi Sanyo, Eisai, EMD Serono, Lilly, Medscape, Merck, Novartis, Onc Live, Peerview, Pieris Pharmaceuticals, Takeda Research Funding: Bristol-Myers Squibb (Inst), Lilly (Inst)

Continue Reading
Yasushi Goto, MD
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Specialty: Lung Cancer

Dr. Yasushi Goto is currently the Assistant chief, Division of Thoracic Oncology, of National Cancer Center Hospital, Tokyo. He received his medical and doctorate degree in University of Tokyo. His current main researches are medical oncology (thoracic malignancies) and translational medicine. He has engaged in more than 50 scientific papers including JTO, JCO, Lancet and NEJM. He is a member of steering committee in several global and domestic studies, and the primary investigators of JCOG trial which is evaluating the efficacy of discontinuing PD-L1 axis inhibitors, and others.

He is also a staff in Section of Knowledge Integration of Center for Cancer Genomics and Advanced Therapeutics and Rare Cancer Center, director of patient supportive organizations, secretary general of JSMO (Japanese Society of Medical Oncology), panel member of guideline and database committee in Japanese Lung Cancer Society, associate editor of Japanese Journal of Clinical Oncology and communication committee member of IASLC.

Disclosures

Honoraria: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Japan, Chugai Pharma, Lilly Japan, MSD, Novartis, Ono Pharmaceutical, Pfizer, Shionogi, Taiho Pharmaceutical; Consulting or Advisory Role: AstraZeneca, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo/UCB Japan, GlaxoSmithKline, Guardant Health AMEA, Illumina, Kyorin, Lilly, Novartis, Pfizer, Taiho Pharmaceutical; Research Funding: A2 Healthcare (Inst), Abbvie (Inst), AstraZeneca (Inst), AstraZeneca (Inst), Bristol-Myers Squibb Japan (Inst), Chugai Pharma (Inst), CMIC (Inst), Daiichi Sankyo (Inst), Daiichi Sankyo/UCB Japan (Inst), EPS Holdings (Inst), Genomic Health (Inst), IQvia (Inst), Kyorin (Inst), Lilly Japan (Inst), Merck Serono (Inst), MSD (Inst), Novartis (Inst), Ono Pharmaceutical (Inst), Pfizer (Inst), Taiho Pharmaceutical (Inst), Takeda (Inst)

Continue Reading
We'd love your feedback!
We'd love your feedback!

Welcome to ASCO Direct™

2021 Annual Meeting Highlights

Expert insights into key ASCO21 data that will impact clinical practice and patient care plus complimentary access to 50 official ASCO video presentations and downloadable slides, picked by our Experts.

ASCO Direct is an officially licensed program of the American Society of Clinical Oncology® (ASCO®)

This program is supported by Bristol Myers Squibb and brought to you by Springer Healthcare